Product Overview
Artesunate Injection IP 30 mg is an injectable antimalarial formulation intended for the management of severe malaria. It provides rapid activity against blood-stage malaria parasites and supports the reduction of parasite levels in the bloodstream.
Following administration, Artesunate is rapidly converted to dihydroartemisinin, an active metabolite with potent antimalarial activity. This mechanism enables rapid reduction of malaria parasites and makes injectable Artesunate particularly useful in severe malaria requiring parenteral treatment.
The formulation is administered intravenously or intramuscularly by qualified healthcare professionals. The appropriate dose is determined according to the patient’s body weight, clinical condition, and physician’s assessment.
Key Features
- Rapid-acting injectable antimalarial
- Supports severe malaria management
- Suitable for IV and IM administration
- Helps reduce malaria parasite burden
- Designed for clinical and hospital use
Uses
- Severe malaria
- Malaria requiring injectable antimalarial treatment
- Parenteral antimalarial therapy
How It Works
Artesunate is converted into dihydroartemisinin, which acts against blood-stage malaria parasites and helps rapidly reduce the parasite burden.
Possible Side Effects
- Nausea
- Vomiting
- Headache
- Dizziness
- Injection-site reactions
- Changes in blood cell counts
Precautions
- For use only under medical supervision
- Administration should be performed by qualified healthcare professionals
- Appropriate clinical monitoring is recommended
- Complete follow-up antimalarial therapy as prescribed
- Not intended for self-administration
Storage Instructions
Store in a cool, dry place protected from light and moisture. Keep out of reach of children and use before the expiry date mentioned on the packaging.
